A fully integrated generic injectables company, Chicago-based Meitheal Pharmaceuticals (“Meitheal”), bridges critical gaps in the US healthcare market by supplying high-quality, affordable generic injectables. Their diversified products, ranging from antibiotics, anticoagulants, & muscle relaxants to drugs used in chemotherapy, represent practical solutions for countless patients around the country, as well as Meitheal’s commitment to their care.
Meitheal & KinBio, a rapidly growing biopharmaceutical company based in Rehovot, Israel, are working together via a joint venture to repurpose an existing biologic. Meitheal has met with the FDA & is targeting a BLA submission for late 2023 or early 2024. The Meitheal & KinBio teams wanted to create a new corporate entity (“NewCo”) to hold the commercial intellectual property associated with this repurposed biologic. At approximately the same time as the BLA submission, an IPO is also being planned.